Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. This is an ASCO Meeting Abstract from the 2017 ...

Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include ...